Claudin-1 (CLDN1)

Assets acting on this target.

Class
CLDN1-targeted antibody-drug conjugate (tubulin inhibitor payload)
Pathway
Antibody binds a CLDN1 epitope exposed on tumor cells (normally hidden in tight junctions), internalizes, releases tubulin inhibitor payload

Claudin-1 is a protein that forms tight junctions, the seals between neighboring epithelial cells that control what passes between them. In healthy tissue, most of CLDN1's surface is folded inward at these junctions, largely hidden from circulating antibodies. In many tumors, normal tissue architecture breaks down and CLDN1 becomes exposed on the outer cell surface, creating a recognition site that is far less accessible on well-organized normal epithelium. This selective exposure is exploited by antibody-drug conjugates, which pair an antibody that binds the exposed CLDN1 epitope with a cytotoxic payload, in this case a tubulin inhibitor that blocks the microtubule assembly cells need to divide. After the antibody binds the tumor cell surface, the complex is internalized and processed, releasing the payload inside the cell, where it disrupts the mitotic spindle and triggers cell death. This strategy is explored across solid tumors where CLDN1 becomes aberrantly displayed, aiming to concentrate cytotoxic drug delivery in malignant tissue while limiting exposure of normal organs. It reflects a broader antibody-drug conjugate rationale: using tumor-restricted surface markers as delivery vehicles for potent chemotherapeutic payloads too toxic to administer systemically on their own.

By indication

Related mechanisms

Claudin-1 (CLDN1) drugs compared

2 drugs, stage by indication
2 drugs acting on Claudin-1 (CLDN1): developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
ALE.P02Alentis Therapeutics AGantibody-drug conjugatePhase 1/2Phase 1/2 in Esophageal Squamous Cell Carcinoma; Phase 1/2 in Head and Neck Squamous Cell Carcinoma; Phase 1/2 in Non-Small Cell Lung Cancer
ALE.P03Alentis Therapeutics AGantibody-drug conjugatePhase 1/2Phase 1/2 in Non-Small Cell Lung Cancer

← all mechanisms